NCT02675478View on ClinicalTrials.gov

Phase 1 Study of Quizartinib

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

November 13, 2018

Study Completion Date

November 13, 2018

Conditions
Relapsed AMLRefractory AML
Interventions
DRUG

AC220

Trial Locations (1)

Unknown

Tokyo

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY

NCT02675478 - Phase 1 Study of Quizartinib | Biotech Hunter | Biotech Hunter